We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.76% | 7.97 | 7.95 | 8.00 | 8.08 | 7.90 | 7.96 | 2,135,086 | 21:19:41 |
From May 2019 to May 2024
By Kim Richters
Bayer AG over the weekend presented two new studies and results for its blood thinner Xarelto.
The German pharmaceutical and chemical company said the drug plus aspirin reduces the combined risk of limb ischemia and major cardiovascular events for patients who have a symptomatic peripheral artery disease after revascularization.
The results are from the Phase 3 VOYAGER PAD study, the company said.
Another study showed that Xarelto lowers the risk of major venous thromboembolism after minor orthopaedic surgery, Bayer said.
This data is from the from the clinical Phase 3 trial PRONOMOS, it said.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
March 30, 2020 02:39 ET (06:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
